Pyrazinamide resistance is caused by two distinct mechanisms: Prevention of coenzyme a depletion and loss of virulence factor synthesis

ACS Infectious Diseases

Volumn 2, Issue 9, 2016, Pages 616-626

  Gopal, Pooja ^a   Yee, Michelle ^a   Sarathy, Jickky ^a   Liang Low, Jian ^a   Sarathy, Jansy P ^b   Kaya, Firat ^b   Dartois, Veronique ^b   Gengenbacher, Martin ^a   Dick, Thomas ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Mechanism Of Action; Pyrazinamide; Pyrazinoic Acid; Resistance; Tuberculosis

Indexed keywords

ACYL CARRIER COENZYME A; ASPARTATE DECARBOXYLASE; BENZOIC ACID; CIPROFLOXACIN; COENZYME A; FATTY ACID SYNTHASE; ISONIAZID; NICOTINIC ACID; PHTHIOCEROL DIMYCOCEROSATE; POLYKETIDE SYNTHASE; PYRAZINOIC ACID; RIBOSOME PROTEIN; RIBOSOME PROTEIN S1; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG; VIRULENCE FACTOR; ASPARTATE 4-DECARBOXYLASE; BACTERIAL PROTEIN; CARBOXYLYASE; PYRAZINAMIDE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CROSS RESISTANCE; FRAMESHIFT MUTATION; IN VITRO STUDY; LOSS OF FUNCTION MUTATION; MINIMUM INHIBITORY CONCENTRATION; MISSENSE MUTATION; MUTATION RATE; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; WHOLE GENOME SEQUENCING; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MICROBIOLOGY; MYCOBACTERIUM BOVIS; TUBERCULOSIS;

BACTERIAL PROTEINS; CARBOXY-LYASES; COENZYME A; DRUG RESISTANCE, BACTERIAL; HUMANS; MUTATION, MISSENSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; POLYKETIDE SYNTHASES; PYRAZINAMIDE; TUBERCULOSIS; VIRULENCE FACTORS;

EID: 85009060616     PISSN: None     EISSN: 23738227     Source Type: Journal    
DOI: 10.1021/acsinfecdis.6b00070     Document Type: Article

References (56)

1. Mitchison, D. A. (1985) The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66, 219-225.
2. Zumla, A. I., Gillespie, S. H., Hoelscher, M., Philips, P. P. J., Cole, S. T., Abubakar, I., McHugh, T. D., Schito, M., Maeurer, M., and Nunn, A. J. (2014) New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect. Dis. 14, 327-340.
3. Zhang, Y., Shi, W., Zhang, W., and Mitchison, D. (2014) Mechanisms of Pyrazinamide Action and Resistance. Microbiol. Spectrum 2, 1-12.
4. Scorpio, A., and Zhang, Y. (1996) Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2, 662-667.
5. Via, L. E., Savic, R., Weiner, D. M., Zimmerman, M. D., Prideaux, B., Irwin, S. M., Lyon, E., O'Brien, P., Gopal, P., Eum, S., Lee, M., Lanoix, J.-P., Dutta, N. K., Shim, T., Cho, J. S., Kim, W., Karakousis, P. C., Lenaerts, A., Nuermberger, E., Barry, C. E., and Dartois, V. (2015) Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives. ACS Infect. Dis. 1, 203-214.
6. Zhang, Y., Scorpio, A., Nikaido, H., and Sun, Z. (1999) Role of Acid pH and Deficient Efflux of Pyrazinoic Acid in Unique Susceptibility of Mycobacterium tuberculosis to Pyrazinamide. J. Bacteriol. 181, 2044-2049.
7. Zhang, Y., Zhang, H., and Sun, Z. (2003) Susceptibility of Mycobacterium tuberculosis to weak acids. J. Antimicrob. Chemother. 52, 56-60.
8. Zhang, Y., and Mitchison, D. (2003) The curious characteristics of pyrazinamide: A review. Int. J. Tuberc Lung Dis 7, 6-21.
9. Zimhony, O., Cox, J. S., Welch, J. T., Vilcheze, C., and Jacobs, W. R. (2000) Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat. Med. 6, 1043-1047.
10. Boshoff, H. I., Mizrahi, V., and Barry, C. E. (2002) Effects of Pyrazinamide on Fatty Acid Synthesis by Whole Mycobacterial Cells and Purified Fatty Acid Synthase I. J. Bacteriol. 184, 2167-2172.
11. Shi, W., Zhang, X., Jiang, X., Yuan, H., Lee, J. S., Barry, C. E., Wang, H., Zhang, W., and Zhang, Y. (2011) Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis. Science 333, 1630-1632.
12. Alexander, D. C., Ma, J. H., Guthrie, J. L., Blair, J., Chedore, P., and Jamieson, F. B. (2012) Gene Sequencing for Routine Verification of Pyrazinamide Resistance in Mycobacterium tuberculosis: A Role for pncA but Not rpsA. J. Clin Microbiol 50, 3726-3728.
13. Xia, Q., Zhao, L.-l., Li, F., Fan, Y.-m., Chen, Y.-y., Wu, B.-b., Liu, Z.-w., Pan, A.-z., and Zhu, M. (2015) Phenotypic and Genotypic Characterization of Pyrazinamide Resistance among Multidrug-resistant Tuberculosis isolates in Zhejiang, China. Antimicrob. Agents Chemother. 59, 1690-1695.
14. Akhmetova, A., Kozhamkulov, U., Bismilda, V., Chingissova, L., Abildaev, T., Dymova, M., Filipenko, M., and Ramanculov, E. (2015) Mutations in the pncA and rpsA genes among 77 Mycobacterium tuberculosis isolates in Kazakhstan. Int. J. Tuberc Lung Dis 19, 179-184.
15. Scorpio, A., Lindholm-Levy, P., Heifets, L., Gilman, R., Siddiqi, S., Cynamon, M., and Zhang, Y. (1997) Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 41, 540-543.
16. Zhang, S., Chen, J., Shi, W., Liu, W., Zhang, W., and Zhang, Y. (2013) Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerging Microbes Infect. 2, e34.
17. Shi, W., Chen, J., Feng, J., Cui, P., Zhang, S., Weng, X., Zhang, W., and Zhang, Y. (2014) Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis. Emerging Microbes Infect. 3, e58.
18. Dillon, N. A., Peterson, N. D., Rosen, B. C., and Baughn, A. D. (2014) Pantothenate and Pantetheine Antagonize the Antitubercular Activity of Pyrazinamide. Antimicrob. Agents Chemother. 58, 7258-7263.
19. Stoffels, K., Mathys, V., Fauville-Dufaux, M., Wintjens, R., and Bifani, P. (2012) Systematic Analysis of Pyrazinamide-Resistant Spontaneous Mutants and Clinical Isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56, 5186-5193.
20. Casali, N., Nikolayevskyy, V., Balabanova, Y., Harris, S. R., Ignatyeva, O., Kontsevaya, I., Corander, J., Bryant, J., Parkhill, J., Nejentsev, S., Horstmann, R. D., Brown, T., and Drobniewski, F. (2014) Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat. Genet. 46, 279-286.
21. Miotto, P., Cabibbe, A. M., Feuerriegel, S., Casali, N., Drobniewski, F., Rodionova, Y., Bakonyte, D., Stakenas, P., Pimkina, E., Augustynowicz-Kopeci, E., Degano, M., Ambrosi, A., Hoffner, S., Mansjo, M., Werngren, J., Rusch-Gerdes, S., Niemann, S., and Cirillo, D. M. (2014) Mycobacterium tuberculosis Pyrazinamide Resistance Determinants: A Multicenter Study. mBio 5, e01819.
22. den Hertog, A. L., Sengstake, S., and Anthony, R. M. (2015) Pyrazinamide resistance in Mycobacterium tuberculosis fails to bite? Pathog. Dis. 73, 10.1093/femspd/ftv037.
23. Bradley, P., Gordon, N. C., Walker, T. M., Dunn, L., Heys, S., Huang, B., Earle, S., Pankhurst, L. J., Anson, L., de Cesare, M., Piazza, P., Votintseva, A. A., Golubchik, T., Wilson, D. J., Wyllie, D. H., Diel, R., Niemann, S., Feuerriegel, S., Kohl, T. A., Ismail, N., Omar, S. V., Smith, E. G., Buck, D., McVean, G., Walker, A. S., Peto, T. E. A., Crook, D. W., and Iqbal, Z. (2015) Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis. Nat. Commun. 6, 10063.
24. McDermott, W., and Tomsett, R. (1954) Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am. Rev. Tuberc 70, 748-754.
25. Peterson, N. D., Rosen, B. C., Dillon, N. A., and Baughn, A. D. (2015) Uncoupling Environmental pH and Intrabacterial Acidification from Pyrazinamide Susceptibility in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 59, 7320-7326.
26. Koller, F., and Leuthardt, F. (1934) Nekrose Und Autolyse.Beitrag Zur Kenntnis Der Dystrophischen Verkalkung. Klin. Wochenschr. 13, 1527-1529.
27. Gopal, P., and Dick, T. (2014) Reactive dirty fragments: implications for tuberculosis drug discovery. Curr. Opin. Microbiol. 21, 7-12.
28. Lanoix, J.-P., Ioerger, T., Ormond, A., Kaya, F., Sacchettini, J., Dartois, V., and Nuermberger, E. (2016) Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum. Antimicrob. Agents Chemother. 60, 735-743.
29. Lenaerts, A., Barry, C. E., and Dartois, V. (2015) Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev. 264, 288-307.
30. Irwin, S. M., Prideaux, B., Lyon, E. R., Zimmerman, M. D., Brooks, E. J., Schrupp, C. A., Chen, C., Reichlen, M. J., Asay, B. C., Voskuil, M. I., Nuermberger, E. L., Andries, K., Lyons, M. A., Dartois, V., and Lenaerts, A. J. (2016) Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ. Mice. ACS Infect. Dis. 2, 251-267.
31. Lanoix, J.-P., Tasneen, R., O'Brien, P., Sarathy, J., Safi, H., Pinn, M., Alland, D., Dartois, V., and Nuermberger, E. (2016) High systemic exposure of pyrazinoic acid has limited anti-Tuberculosis activity in murine and rabbit models of tuberculosis. Antimicrob. Agents Chemother. 60, 4197.
32. Pethe, K., Sequeira, P. C., Agarwalla, S., Rhee, K., Kuhen, K., Phong, W. Y., Patel, V., Beer, D., Walker, J. R., Duraiswamy, J., Jiricek, J., Keller, T. H., Chatterjee, A., Tan, M. P., Ujjini, M., Rao, S. P. S., Camacho, L., Bifani, P., Mak, P. A., Ma, I., Barnes, S. W., Chen, Z., Plouffe, D., Thayalan, P., Ng, S. H., Au, M., Lee, B. H., Tan, B. H., Ravindran, S., Nanjundappa, M., Lin, X., Goh, A., Lakshminarayana, S. B., Shoen, C., Cynamon, M., Kreiswirth, B., Dartois, V., Peters, E. C., Glynne, R., Brenner, S., and Dick, T. (2010) A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat. Commun. 1, 1-8.
33. Stanley, S. A., Grant, S. S., Kawate, T., Iwase, N., Shimizu, M., Wivagg, C., Silvis, M., Kazyanskaya, E., Aquadro, J., Golas, A., Fitzgerald, M., Dai, H., Zhang, L., and Hung, D. T. (2012) Identification of Novel Inhibitors of M.Tuberculosis Growth Using Whole Cell Based High-Throughput Screening. ACS Chem. Biol. 7, 1377-1384.
34. Cox, J. S., Chen, B., McNeil, M., and Jacobs, W. R. (1999) Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature 402, 79-83.
35. Camacho, L. R., Ensergueix, D., Perez, E., Gicquel, B., and Guilhot, C. (1999) Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-Tagged transposon mutagenesis. Mol. Microbiol. 34, 257-267.
36. Keating, L. A., Wheeler, P. R., Mansoor, H., Inwald, J. K., Dale, J., Hewinson, R. G., and Gordon, S. V. (2005) The pyruvate requirement of some members of the Mycobacterium tuberculosis complex is due to an inactive pyruvate kinase: implications for in vivo growth. Mol. Microbiol. 56, 163-174.
37. Gopalan, G., Chopra, S., Ranganathan, A., and Swaminathan, K. (2006) Crystal structure of uncleaved L-Aspartate-decarboxylase from Mycobacterium tuberculosis. Proteins: Struct., Funct., Genet. 65, 796-802.
38. Pansy, F., Stander, H., and Donovick, R. (1952) In vitro studies on isonicotinic acid hydrazide. Am. Rev. Tuberc. 65, 761-764.
39. Mariam, D. H., Mengistu, Y., Hoffner, S. E., and Andersson, D. I. (2004) Effect of rpoB Mutations Conferring Rifampin Resistance on Fitness of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48, 1289-1294.
40. Zimhony, O., Vilcheize, C., Arai, M., Welch, J. T., and Jacobs, W. R. (2007) Pyrazinoic Acid and Its n-Propyl Ester Inhibit Fatty Acid Synthase Type I in Replicating Tubercle Bacilli. Antimicrob. Agents Chemother. 51, 752-754.
41. Azad, A. K., Sirakova, T. D., Rogers, L. M., and Kolattukudy, P. E. (1996) Targeted replacement of the mycocerosic acid synthase gene in Mycobacterium bovis BCG produces a mutant that lacks mycosides. Proc. Natl. Acad. Sci. U. S. A. 93, 4787-4792.
42. Azad, A. K., Sirakova, T. D., Fernandes, N. D., and Kolattukudy, P. E. (1997) Gene Knockout Reveals a Novel Gene Cluster for the Synthesis of a Class of Cell Wall Lipids Unique to Pathogenic Mycobacteria. J. Biol. Chem. 272, 16741-16745.
43. Camacho, L. R., Constant, P., Raynaud, C., Laneielle, M.-A., Triccas, J. A., Gicquel, B., Daffei, M., and Guilhot, C. (2001) Analysis of the Phthiocerol Dimycocerosate Locus ofMycobacterium tuberculosis: EVIDENCE THAT THIS LIPID IS INVOLVED IN THE CELL WALL PERMEABILITY BARRIER. J. Biol. Chem. 276, 19845-19854.
44. Tarshis, M. S., and Weed, W. A. J. (1953) Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media. Am. Rev. Tuberc. 67, 391-395.
45. Yeager, R. L., Munroe, W. G., and Dessau, F. I. (1952) Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Am. Rev. Tuberc. 65, 523-546.
46. Malone, L., Schurr, A., Lindh, H., McKenzie, D., Kiser, J. S., and Williams, J. H. (1952) The effect of pyrazinamide (aldinamide) on experimental tuberculosis in mice. Am. Rev. Tuberc. 65, 511-518.
47. Chernyaeva, E. N., Shulgina, M. V., Rotkevich, M. S., Dobrynin, P. V., Simonov, S. A., Shitikov, E. A., Ischenko, D. S., Karpova, I. Y., Kostryukova, E. S., Ilina, E. N., Govorun, V. M., Zhuravlev, V. Y., Manicheva, O. A., Yablonsky, P. K., Isaeva, Y. D., Nosova, E. Y., Mokrousov, I. V., Vyazovaya, A. A., Narvskaya, O. V., Lapidus, A. L., and O'Brien, S. J. (2014) Genome-wide Mycobacterium tuberculosis variation (GMTV) database: A new tool for integrating sequence variations and epidemiology. BMC Genomics 15, 1-8.
48. Ali, A., Hasan, Z., McNerney, R., XXMallard, K., Hill-Cawthorne, G., Coll, F., Nair, M., Pain, A., Clark, T. G., and Hasan, R. (2015) Whole Genome Sequencing Based Characterization of Extensively Drug-Resistant Mycobacterium tuberculosis Isolates from Pakistan. PLoS One 10, e0117771.
49. Manca, C., Koo, M.-S., Peixoto, B., Fallows, D., Kaplan, G., and Subbian, S. (2013) Host Targeted Activity of Pyrazinamide in Mycobacterium tuberculosis Infection. PLoS One 8, e74082.
50. Almeida, D. V., Tyagi, S., Li, S., Wallengren, K., Pym, A. S., Ammerman, N. C., Bishai, W. R., and Grosset, J. H. (2014) Revisiting Anti-Tuberculosis Activity of Pyrazinamide in Mice. Mycobac Dis 4, 145.
51. Zhang, Y., Permar, S., and Sun, Z. (2002) Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51, 42-49.
52. Cui, Z., Wang, J., Lu, J., Huang, X., Zheng, R., and Hu, Z. (2013) Evaluation of Methods for Testing the Susceptibility of Clinical Mycobacterium tuberculosis Isolates to Pyrazinamide. J. Clin Microbiol 51, 1374-1380.
53. Kaser, M., Ruf, M.-T., Hauser, J., Marsollier, L., and Pluschke, G. (2009) Optimized Method for Preparation of DNA from Pathogenic and Environmental Mycobacteria. Appl. Environ. Microbiol. 75, 414-418.
54. Stover, C. K., de la Cruz, V. F., Fuerst, T. R., Burlein, J. E., Benson, L. A., Bennett, L. T., Bansal, G. P., Young, J. F., Lee, M. H., Hatfull, G. F., Snapper, S. B., Barletta, R. G., Jacobs, W. R., and Bloom, B. R. (1991) New use of BCG for recombinant vaccines. Nature 351, 456-460.
55. Jain, M., Petzold, C. J., Schelle, M. W., Leavell, M. D., Mougous, J. D., Bertozzi, C. R., Leary, J. A., and Cox, J. S. (2007) Lipidomics reveals control of Mycobacterium. Proc. Natl. Acad. Sci. U. S. A. 104, 5133.
56. Bachmann, B. O., and Ravel, J. (2009) Methods in Enzymology, Chapter 8, pp 181-217, Academic Press.